- Ruspharmtech Company News Section

Ruspharmtech Information
  • Anastasia
  • URL:
  • The scientific-research company Russian Pharmaceutical Technologies was founded in 2012 in Saint-Petersburg. The main project was the development of the allosteric inhibitor FGFR2-alofanib. Since 2012 the company is a resident of the Skolkovo fund. Preclinical studies were implemented with grant support from the foundation.
Ruspharmtech Press Release -

  • Ruspharmtech got a US patent for Alofanib
  • Company “Russian Pharmaceutical Technologies” (Ruspharmtech) has increased the commercial value of its patent profile by receiving an American patent. The document contains information about originality and innovativeness of company’s development - the drug alofanib, which is the first of class allosteric inhibitor of fibroblast growth factor receptor type 2 (FGFR2) intended for cancer treatment.
  • The Russian company «Ruspharmtech» got a US patent for Alofanib - the first of the class allosteric inhibitor of FGFR2 for cancer treatment.
  • March 28, 2018